When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges

被引:3
|
作者
Speight, Beverley [1 ]
Tischkowitz, Marc [1 ,2 ]
机构
[1] Addenbrookes Hosp, East Anglian Med Genet Serv, Addenbrookes Treatment Ctr, Cambridge Biomed Campus,Box 134,Level 6, Cambridge CB2 0QQ, England
[2] Univ Cambridge, Acad Dept Med Genet, Cambridge, England
基金
欧洲研究理事会;
关键词
BRCA1/BRCA2; Ovariancancer; Risk-reducing breast surgery; Genetic counseling; BREAST-CANCER; BRCA2; MUTATIONS; WOMEN; SURVIVAL; ASSOCIATION;
D O I
10.1007/s10897-017-0136-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations in BRCA1/BRCA2 significantly increase the risk of breast and ovarian cancer in women. This case report describes a BRCA1 germline mutation identified in a woman with stage IV epithelial ovarian cancer and the provision of genetic counseling about BRCA1-associated breast cancer risk in the three years following diagnosis. The report centers on the patient's enquiry about risk-reducing breast surgery. We focus on the challenges for health professionals and patients in understanding and balancing the risks and benefits of major prophylactic surgery in the context of a potentially life-limiting cancer diagnosis. Breast cancer risk management in BRCA1/BRCA2 carriers with advanced ovarian cancer is an under-explored area of genetic counseling research. This article includes a case report, a review of the relevant literature and considers some implications for practice.
引用
收藏
页码:1173 / 1178
页数:6
相关论文
共 50 条
  • [41] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Metcalfe, K.
    Gershman, S.
    Lynch, H. T.
    Ghadirian, P.
    Tung, N.
    Kim-Sing, C.
    Olopade, O. I.
    Domchek, S.
    McLennan, J.
    Eisen, A.
    Foulkes, W. D.
    Rosen, B.
    Sun, P.
    Narod, S. A.
    BRITISH JOURNAL OF CANCER, 2011, 104 (09) : 1384 - 1392
  • [42] The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers
    Borreani, C.
    Manoukian, S.
    Bianchi, E.
    Brunelli, C.
    Peissel, B.
    Caruso, A.
    Morasso, G.
    Pierotti, M. A.
    CLINICAL GENETICS, 2014, 85 (01) : 7 - 15
  • [43] Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer
    de Matos, Leonor Vasconcelos
    Fernandes, Leonor
    Louro, Pedro
    Placido, Ana
    Barros, Manuel
    Vaz, Fatima
    CURRENT ONCOLOGY, 2021, 28 (01) : 485 - 490
  • [44] Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations
    Kauff, ND
    Scheuer, L
    Robson, ME
    Glogowski, E
    Kelly, B
    Barakat, R
    Heerdt, A
    Borgen, PI
    Davis, JG
    Offit, K
    GENETICS IN MEDICINE, 2001, 3 (06) : 422 - 425
  • [45] Psychological implications of risk-reducing mastectomies in BRCA1/2 mutation carriers
    Luque Suarez, Sofia
    Olivares Crespo, Maria Eugenia
    Brenes Sanchez, Juana Maria
    Herrera de la Muela, Maria
    CIRUGIA ESPANOLA, 2022, 100 (01): : 7 - 17
  • [46] Time to decide about risk-reducing mastectomy: A case series of BRCA1/2 gene mutation carriers
    McCullum M.
    Bottorff J.L.
    Kelly M.
    Kieffer S.A.
    Balneaves L.G.
    BMC Women's Health, 7 (1)
  • [47] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Phillips, Kelly-Anne
    Milne, Roger L.
    Rookus, Matti A.
    Daly, Mary B.
    Antoniou, Antonis C.
    Peock, Susan
    Frost, Debra
    Easton, Douglas F.
    Ellis, Steve
    Friedlander, Michael L.
    Buys, Saundra S.
    Andrieu, Nadine
    Nogues, Catherine
    Stoppa-Lyonnet, Dominique
    Bonadona, Valerie
    Pujol, Pascal
    McLachlan, Sue Anne
    John, Esther M.
    Hooning, Maartje J.
    Seynaeve, Caroline
    Tollenaar, Rob A. E. M.
    Goldgar, David E.
    Terry, Mary Beth
    Caldes, Trinidad
    Weideman, Prue C.
    Andrulis, Irene L.
    Singer, Christian F.
    Birch, Kate
    Simard, Jacques
    Southey, Melissa C.
    Olsson, Hakan L.
    Jakubowska, Anna
    Olah, Edith
    Gerdes, Anne-Marie
    Foretova, Lenka
    Hopper, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3091 - 3099
  • [48] Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Oden, Lovisa
    Akbari, Mohammad
    Zaman, Tasnim
    Singer, Christian F.
    Sun, Ping
    Narod, Steven A.
    Salmena, Leonardo
    Kotsopoulos, Joanne
    ONCOTARGET, 2016, 7 (52) : 86687 - 86694
  • [49] Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Jane C. Figueiredo
    Robert W. Haile
    Jonine L. Bernstein
    Current Breast Cancer Reports, 2009, 1 (3) : 139 - 147
  • [50] Cancer risks among BRCA1 and BRCA2 mutation carriers
    E Levy-Lahad
    E Friedman
    British Journal of Cancer, 2007, 96 : 11 - 15